Sanders C C, Sanders W E
Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178.
Eur J Clin Microbiol. 1987 Aug;6(4):435-8. doi: 10.1007/BF02013106.
The clinical problems caused by inducible beta-lactamases in certain gram-negative bacteria are being recognized with increasing frequency. These problems include the rapid emergence of multiple beta-lactam resistance during therapy with many of the newer beta-lactam antibiotics. Such multiply resistant organisms are now spreading within the hospital and have become important nosocomial pathogens. This has been a particularly difficult problem for intensive care units, cystic fibrosis centers and burn units where there are clusters of patients who are highly susceptible to infections with organisms like Enterobacter spp., Serratia spp. and Pseudomonas aeruginosa, which possess inducible beta-lactamases. Only through an awareness of these problems, their cause, and restriction of the use of certain newer beta-lactam antibiotics can these problems be controlled.
某些革兰氏阴性菌中诱导型β-内酰胺酶引起的临床问题正越来越频繁地被认识到。这些问题包括在使用许多新型β-内酰胺抗生素治疗期间多重β-内酰胺耐药性的迅速出现。这种多重耐药菌目前正在医院内传播,并已成为重要的医院病原体。对于重症监护病房、囊性纤维化中心和烧伤病房来说,这一直是个特别棘手的问题,因为这些地方有一群对肠杆菌属、沙雷氏菌属和铜绿假单胞菌等具有诱导型β-内酰胺酶的生物体感染高度易感的患者。只有通过认识到这些问题、其成因,并限制某些新型β-内酰胺抗生素的使用,才能控制这些问题。